Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081] Medicine Not selected 16 May 2025 Diltiazem (Anatop, SLV-324, VEN 307) for Anal fissure [TSID 12100] Medicine Not ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology, recommended by NICE.

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. These cookies remember ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

The technology aims to significantly reduce waiting times by efficiently triaging patients with suspicious skin lesions. DERM (Deep Ensemble for Recognition of Malignancy), developed by Skin Analytics ...

Optimised final draft guidance published today recommends 12 SQ-HDM SLIT, also known as Acarizax and made by ALK-Abello, as an option for treating persistent moderate to severe house dust mite ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We need to prioritise areas of guidance development and delivery that will have the greatest impact on the health and care system. To do this we're developing a new centralised approach.